Amino acid and acylcarnitine levels relate with chronic schizophrenia
Poster (download)
[pdf-embedder url=”https://bgrssb.icgbio.ru/wp-content/uploads/2020/07/285.pdf”]
Irina Mednova1, Alexandr Chernonosov2, Marat Kasakin3, Elena Kornetova4, Arkadiy Semke5, Nikolay Bokhan6, Vladimir Koval7, Svetlana Ivanova8
1Mental Health Research Institute, TNRMC, Tomsk, Russia, irinka145@yandex.ru
2Institute of Chemical Biology and Fundamental Medicine SB RAS, Novosibirsk, Russia, alexander.chernonosov@niboch.nsc.ru
3Institute of Chemical Biology and Fundamental Medicine SB RAS, Novosibirsk, Russia, kassakinm@gmail.com
4Mental Health Research Institute, TNRMC, Tomsk, Russia, kornetova@sibmail.com
5Mental Health Research Institute, TNRMC, Tomsk, Russia, asemke@mail.ru
6Mental Health Research Institute, TNRMC, Tomsk, Russia, mental@tnimc.ru
7Institute of Chemical Biology and Fundamental Medicine SB RAS, Novosibirsk, Russia, koval@niboch.nsc.ru
8Mental Health Research Institute, TNRMC, Tomsk, Russia, ivanovaniipz@gmail.com
Amino acids and acylcarnitines play important role as substrates and intermediate products in the most pathways related with schizophrenia. We found a significant decrease in the concentration of valine, aspartate, citrulline, glycine, arginine, glutamate and ornithine as well as C14, C14OH, C16OH, C16:1, C16:1OH, РЎ18, C18OH, C18:1, РЎ18:1OH, C18:2OH and C5:1 and increase C4DC in patients with schizophrenia in comparison to the controls.